Abstract Submission Guidelines

INSTRUCTIONS - CONTENT

- The abstract title should clearly define the content of the paper.
- Do not use abbreviations in the title of your abstract.
- The space allowed for the main body of the abstract is 350 words.
- Abstracts must be submitted and presented in English.
- If your studies have been supported by a grant, please indicate the source of funding at the end of your abstract.
- Proprietary names of drugs are not allowed - the generic names must be used.
- Number references (if any) in the order in which they appear in the abstract.
- If there are multiple abstract submissions by the same authors, please maintain consistency in the authors' names in order to avoid incorrect duplication in the author index.
- Do not split data to create several abstracts from one data set.
- Abstracts will be published exactly as submitted so please take care and proof read your abstract before submitting it.
- Work which has been previously presented may be submitted for presentation at the meeting provided it has not been published as a full manuscript.

PLEASE STRUCTURE YOUR ABSTRACT AS FOLLOWS:

Research abstracts:
- Objectives
- Methods
- Results
- Conclusion

Clinical cases:
- Background
- Presenting problem
- Clinical management
- Discussion

CONFLICT OF INTEREST
- Presenters must disclose any possible conflicts of interest by following the instructions on the abstract form.
• Conflict of interest statements will be published with the abstracts.

ETHICS
Submission of an abstract that deals with experimentation on humans or animals implies that the authors adhere to any applicable guidelines dealing with human or animal experimentation and that the appropriate approval has been granted from the institution’s review committees.

NEW INVESTIGATOR AWARDS
To be eligible for a New Investigator Award an author must be:
1. First and presenting author
2. Must be in training or within 3 years of attaining PhD or MD or equivalent and/or aged under 35

Please upload your confirmation of eligibility form where shown.

New Investigator Awards will be offered according to mean score achieved during the blind reviewing process. Awards winners will be notified by email by 20 May 2022.

COMMITMENT
1. Submission of abstract constitutes a commitment on behalf of the authors that the abstract will be presented as accepted.
2. Expenses associated with the preparation, submission and presentation of an abstract are the responsibility of the author(s).
3. On acceptance of the abstract, the presenting author must register before 27 May 2022. Failure to do so may result in their abstract being removed from the programme.

AMENDING A SUBMISSION
You may wish to change your submission. You can do this at any time up to the deadline by logging onto the abstract submission system.

WHAT HAPPENS AFTER I SUBMIT MY ABSTRACT?
You will receive an email to confirm that your abstract has been received. After the abstract deadline (25 April 2022) all abstracts will be reviewed blind by a panel of experts. Mean scores will be calculated for each abstract and based on this they will be allocated to oral or poster sessions, or they may be rejected.

You will be informed about the acceptance or otherwise of your abstract, and the form of presentation, on 20 May 2022.

HOW IS MY ABSTRACT SCORED?
Your abstract will be scored based on the following criteria:
• Scientific merit
• Originality
• Methodology
• Conclusions supported by appropriate data

Research abstracts with no data are unlikely to be accepted.

Clinical cases will be judged according to the level of interest, and the quality of the description of the case, analysis and discussion.

**CAN I WITHDRAW MY ABSTRACT AFTER SUBMISSION?**
If you need to withdraw your abstract please contact us at the address below.

**SECRETARIAT**
Please contact in the case of enquiries or problems:

Janet Crompton  
Abstracts Administrator  
14th International Conference on Osteogenesis Imperfecta  
30 August – 2 September 2022  
Sheffield, UK  
Web: https://oi2022.org  
iccbh@ectsoc.org